Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY

v3.20.2
STOCKHOLDERS' EQUITY
9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
STOCKHOLDERS' EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY 


Common stock issued


On February 12, 2020, Duos Technologies Group, Inc., a Florida corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), as representative of the underwriters listed therein (the “Underwriters”), pursuant to which the Company agreed to sell to the Underwriters in a firm commitment underwritten public offering (the “Offering”) an aggregate of 1,350,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a public offering price of $6.00 per share. In addition, the Underwriters were granted an over-allotment option (the “Over-allotment Option”) for a period of 45 days to purchase up to an additional 202,500 shares of Common Stock. The Offering closed on February 18, 2020. The Common Stock began trading on the Nasdaq Capital Market under the symbol DUOT on February 13, 2020.


On February 20, 2020, pursuant to and in compliance with the terms and conditions of the aforementioned Underwriting Agreement and the Offering, the Underwriters provided notice that they would partially exercise the Over-allotment Option to purchase 192,188 shares of Common Stock at $6.00 per share (the “Over-Allotment Exercise”). The sale of the Over-Allotment Exercise to purchase 192,188 shares of Common Stock closed on February 21, 2020.


In total, the Company issued 1,542,188 shares of common stock in connection with these underwritten public offerings and up listing to the Nasdaq Capital Market national exchange.  The securities were issued pursuant to a Registration Statement on Form S-1 (File No. 333- 235455), as amended, which was declared effective by the United States Securities and Exchange Commission on February 12, 2020 (the “Registration Statement”). The Company received gross proceeds of approximately $9.25 million for the Offering to date, including the exercise of the Over-Allotment Exercise, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.


Stock-Based Compensation


Stock-based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2020 and 2019, was $364,561 and $35,017, respectively, for stock options granted to employees and directors. This expense is included in selling, general and administrative expenses in the unaudited consolidated statements of operations. Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. At September 30, 2020, the total compensation cost for stock options not yet recognized was $310,040. This cost will be recognized over the remaining vesting term of the options of approximately one year.


Employee Stock Options


A maximum of 178,572 shares were made available for grant under the 2016 Plan, as amended, and all outstanding options under the Plan provide a cashless exercise feature. The maximum number of shares was increased by shareholder approval to 321,429.  The identification of individuals entitled to receive awards, the terms of the awards, and the number of shares subject to individual awards, are determined by our Board of Directors or the Compensation Committee, at their sole discretion. The aggregate number of shares with respect to which options or stock awards may be granted under the 2016 Plan and the purchase price per share, if applicable, shall be adjusted for any increase or decrease in the number of issued shares resulting from a stock dividend, stock split, reverse stock split, recapitalization or similar event. As of September 30, 2020, and December 31, 2019, options to purchase 411,898 shares of common stock and 163,010 shares of common stock were outstanding under the 2016 Plan, respectively. On April 1, 2020 the Board of Directors cancelled 161,402 options previously granted to existing employees and granted 310,290 options, of which 160,866 were replaced with new options carrying a $6.00 exercise price, 536 options were forfeited and a further 149,424 options were issued to existing employees, officers and directors carrying a $4.74 strike price with a vesting period ranging from 9 months to 21 months. The new stock options issued have a fair value of $370,312. The options that were cancelled and replaced were accounted for by valuing the original options on the day before they were cancelled and valuing the new options on the day of issuance. The inputs used were a stock price of $4.74 on the day of cancellation and $4.70 on the day of issuance, expected term of 2.5 years, expected volatility of 81%, no anticipated dividend and an interest rate of $0.255%. The difference between the valuations were recorded as one-time option expense given that options cancelled were already vested and the replacement options were immediately vested. The one-time expense for this cancellation and issuance was $102,800. The strike price of the cancelled options was $14.00.


During the current quarter, the Company’s Board of Directors granted 100,000 new stock options with a strike price of $4.18 per share to its new Chief Executive Officer.  These options were awarded as a one-time award as a hiring incentive and have a fair value of $193,388. The issuance of these options generated with stock option compensation expense this quarter in the amount of $11,921 and a balance of unamortized stock option compensation expense of $181,467, that will be expensed over the next 1.75 years.  In addition, 50,358 options previously issued to the Company’s former CEO became fully vested during the quarter and generated a stock option compensation expense in the amount of $95,127.


The Company has no expired employee stock options under the 2016 Plan at September 30, 2020 and 2019.


 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregate

 

 

 

 

 

 

 

Exercise

 

 

Contractual

 

 

Intrinsic

 

 

 

 

Shares

 

 

Price

 

 

Term (Years)

 

 

Value

 

Outstanding at December 31, 2018

 

 

 

160,143

 

 

$

14.00

 

 

 

4.4

 

 

 

—

 

Granted

 

 

 

8,572

 

 

$

14.00

 

 

 

5.0

 

 

 

—

 

Forfeited

 

 

 

(14,286

)

 

$

14.00

 

 

 

—

 

 

 

—

 

Outstanding at September 30, 2019

 

 

 

154,429

 

 

$

14.00

 

 

 

3.4

 

 

 

—

 

Exercisable at September 30, 2019

 

 

 

145,857

 

 

$

14.00

 

 

 

3.4

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2019

 

 

 

163,010

 

 

$

14.00

 

 

 

3.4

 

 

 

—

 

Granted

 

 

 

410,290

 

 

$

5.08

 

 

 

4.6

 

 

 

—

 

Cancelled/forfeited

 

 

 

(161,402

)

 

$

14.00

 

 

 

—

 

 

 

—

 

Outstanding at September 30, 2020

 

 

 

411,898

 

 

$

5.13

 

 

 

4.6

 

 

 

—

 

Exercisable at September 30, 2020

 

 

 

212,832

 

 

$

5.76

 

 

 

4.5

 

 

 

—

 


Warrants


The following is a summary of activity for warrants to purchase common stock for the nine months ended September 30, 2020:


 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Intrinsic

 

 

 

Warrants

 

 

Price

 

 

Term (Years)

 

 

Value

 

Outstanding at December 31, 2018

 

 

1,815,182

 

 

$

9.52

 

 

 

3.9

 

 

 

—

 

Warrants expired, forfeited, cancelled or exercised

 

 

(327,612

)

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at September 30, 2019

 

 

1,487,570

 

 

$

8.78

 

 

 

2.8

 

 

 

—

 

Exercisable at September 30, 2019

 

 

1,487,570

 

 

$

8.78

 

 

 

2.8

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2019

 

 

1,521,250

 

 

$

8.78

 

 

 

3.0

 

 

 

—

 

Warrants expired, forfeited, cancelled or exercised

 

 

(10,647

)

 

 

 

 

 

 

 

 

 

 

 

 

Warrants issued

 

 

76,950

 

 

$

9.00

 

 

 

2.6

 

 

 

—

 

Outstanding at September 30, 2020

 

 

1,587,553

 

 

$

8.69

 

 

 

2.2

 

 

 

—

 

Exercisable at September 30, 2020

 

 

1,587,553

 

 

$

8.69

 

 

 

2.2

 

 

 

—

 


Warrants issued were for the underwriters of the registered direct offering completed in the first quarter of 2020. They carry a strike price of $9.00 representing 150% of the offering price of $6.00 per share and vest 6 months after completion of the offering. In the current quarter, 10,647 warrants were cancelled of which 9,450 were exchanged for new warrants with the same terms and 1,197 expired.